Laronidase
- Generic Name
- Laronidase
- Brand Names
- Aldurazyme
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 210589-09-6
- Unique Ingredient Identifier
- WP58SVM6R4
- Background
Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase. It contains 6 N-linked oligosaccharide modification sites.
- Indication
For the treatment of mucopolysaccharidosis
- Associated Conditions
- Mucopolysaccharidosis Type I (MPS I)
- Associated Therapies
- -
China Post-marketing Surveillance (PMS) Study of Aldurazyme®
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 12
- Registration Number
- NCT05134571
- Locations
- 🇨🇳
Investigational Site Number :1560001, Wuhan, China
🇨🇳Investigational Site Number :1560004, Guangzhou, China
🇨🇳Investigational Site Number :1560006, Hangzhou, China
Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 20
- Registration Number
- NCT01572636
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Administration of IV Laronidase Post Bone Marrow Transplant in Hurler
- First Posted Date
- 2010-07-30
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 11
- Registration Number
- NCT01173016
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
- Conditions
- Cognitive DeclineHurler-Scheie SyndromeScheie SyndromeLysosomal Storage DiseaseMucopolysaccharidosis I
- Interventions
- First Posted Date
- 2009-02-27
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Patricia I. Dickson, M.D.
- Target Recruit Count
- 9
- Registration Number
- NCT00852358
- Locations
- 🇺🇸
Los Angeles Biomedical Institute at Harbor-UCLA, Torrance, California, United States
🇺🇸Children's Hospital & Research Center Oakland, Oakland, California, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I
- Conditions
- Spinal Cord CompressionMucopolysaccharidosis IScheie SyndromeHurler-Scheie SyndromeLysosomal Storage Disease
- Interventions
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Patricia I. Dickson, M.D.
- Target Recruit Count
- 3
- Registration Number
- NCT00786968
- Locations
- 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
🇺🇸Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, California, United States
Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I
- Conditions
- Mucopolysaccharidosis ILysosomal Storage DiseasesSpinal Cord Compression
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Patricia I. Dickson, M.D.
- Target Recruit Count
- 4
- Registration Number
- NCT00215527
- Locations
- 🇺🇸
Los Angeles Biomedical Research Institute at Harbor-UCLA ( LA BioMed ), Torrance, California, United States
🇫🇮Helsinki University Central Hospital, Helsinki, Finland
A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients
- Conditions
- Mucopolysaccharidosis IHurler's SyndromeHurler-Scheie SyndromeScheie's Syndrome
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 25
- Registration Number
- NCT00144768
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Childrens Hospital Los Angeles, Los Angles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.